For example, benefits of cetuximab and panitumumab in colorectal cancer and benefits of the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib in NSCLC are respectively associated with presence vs absence of KRAS and EGFR mutations. This evidence concerns the gene EGFR and colorectal cancer.